# Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

2025-04-10

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago. Adlai Nortye has two abstracts scheduled for presentations at AACR.

"We are pleased to present the progress of our innovative pipeline at the upcoming 2025 AACR Annual Meeting. We are especially proud of our R&D capabilities in designing and developing our multi-specific immune-oncology platform, highlighted by AN8025 (αPDL1xLag3variant xCD86variant), and highly innovative small molecule pan-RAS(ON) inhibitors, exemplified by AN9025. This breakthrough work underlines our commitment to delivering transformative therapies for cancer patients," said Archie Tse, MD, PhD, Head of Research and Development at Adlai Nortye.

The title and session information for the poster presentation are listed below.

Poster title: Coordinated stimulation of APC and T cell functions by first-in-class, tri-specific AN8025 for next-generation cancer immunotherapy” (Abstract# 3420)
Date and Time: Monday, April 28, 2025; 2:00 PM - 5:00 PM CT
Session Title: Enhanced Antibodies, TCR Constructs, Cytokines and Chimeric Proteins
Location: Poster Section 35
Poster Board Number: 15

Poster title: AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity (Abstract# 4377)
Date and Time: Tuesday, April 29, 2025; 9:00 AM - 12:00 PM CT
Session Title: RAS Inhibitors
Location: Poster Section 21
Poster Board Number: 12

Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and Presentations section on Adlai Nortye’ website after AACR 2025 conference.

**About AN8025**
AN8025 is a proprietary tri-specific antibody fusion protein derived from an approved αPD-L1 antibody and fused with functionally optimized CD86 and LAG3 variants. Designed to modulate T cell and antigen-presenting cell (APC) functions, preclinical studies have demonstrated that AN8025 enhances both the quantity and quality of APCs while also inducing robust PD-L1-dependent T cell activation and anti-tumor efficacy *in vivo*. The Company plans to submit the IND application in mid-2025.

**About AN9025**
AN9025 is an in-house developed oral small molecule pan-RAS(ON) inhibitor, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have demonstrated that AN9025 effectively inhibits RAS-mutant cancers with potent and durable efficacy, including pancreatic, lung, and colorectal adenocarcinomas, and shows comparable or superior results relative to a benchmark agent of the same class. The company plans to submit an IND application in the second half of 2025.

**About Adlai Nortye**
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on the development of innovative targeted and immune-modulating cancer therapies, with global R&D centers in the U.S. and China. The Company is advancing a robust oncology pipeline, with our lead candidate Buparlisib (AN2025), a pan-PI3K inhibitor, currently being evaluated in a registrational Phase 3 trial (NCT04338399) in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-PD(L)1 treatment. Additionally, we are advancing multiple drug candidates including AN4005, an oral small molecule PD-L1 inhibitor, AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (“APC”) modulator, and AN9025, an oral small molecule pan-RAS(ON) inhibitor.

**Forward-Looking Statement**
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

**Company contact:**
Investor Relations
Email: ir@adlainortye.com